Semnur Pharmaceuticals, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | Apr 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $1.2M | — | $1.3M | — | — | — | $1.1M |
| SG&A Expense | — | $3.0M | — | $3.3M | — | — | — | $151.5M |
| Operating Income | — | $-4.2M | — | $-4.6M | — | — | — | $-152.6M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-4.3M | — | $-4.6M | — | — | — | $-152.6M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.02 | — | $-0.02 | — | — | — | $-0.76 |
| EPS (Diluted) | — | $-0.02 | — | $-0.02 | — | — | — | $-0.76 |
| Shares Outstanding (Basic) | 230.2M | 230.2M | 230.2M | 230.2M | 230.2M | 230.2M | 229.7M | 201.7M |
| Shares Outstanding (Diluted) | 230.2M | 230.2M | 230.2M | 230.2M | 230.2M | 230.2M | 229.7M | 201.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |